Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radotinib in 3rd-line+ CP-CML
NCT02422719Phase 2Unknown
- Sponsor
- Ulsan University Hospital
- Start
- Apr 2015
- Primary completion
- Mar 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of radotinib in chronic myeloid leukemia (CML), sponsored by Ulsan University Hospital. Status: unknown.
02
Drugs
radotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02422719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422719.